
AbbVie and GUBRA Collaborate to Develop New Obesity Treatment: Amylin Analog License Agreement Announced
AbbVie and Gubra Collaborate to Develop a Potential Obesity Treatment On March 3, 2025, AbbVie, a global research-based biopharmaceutical company, and Gubra A/S, a Danish preclinical contract research organization specializing in metabolic and fibrotic diseases, announced a licensing agreement. This collaboration will allow AbbVie to incorporate GUB014295, an amylin peptide developed by Gubra, into its…